[go: up one dir, main page]

SK16452001A3 - FAB-aktivované protinádorové zlúčeniny, ich prekurzory, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty - Google Patents

FAB-aktivované protinádorové zlúčeniny, ich prekurzory, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty Download PDF

Info

Publication number
SK16452001A3
SK16452001A3 SK1645-2001A SK16452001A SK16452001A3 SK 16452001 A3 SK16452001 A3 SK 16452001A3 SK 16452001 A SK16452001 A SK 16452001A SK 16452001 A3 SK16452001 A3 SK 16452001A3
Authority
SK
Slovakia
Prior art keywords
compound
group
formula
cytotoxic
cytostatic
Prior art date
Application number
SK1645-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Pilar Garin-Chesa
Martin Lenter
John Edward Park
Stefan Peters
Wolfgang Rettig
Raymond Armand Firestone
Dietmar Leipert
J�Rgen Mack
Leila A. Telan
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of SK16452001A3 publication Critical patent/SK16452001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK1645-2001A 1999-05-14 2000-05-11 FAB-aktivované protinádorové zlúčeniny, ich prekurzory, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty SK16452001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13413699P 1999-05-14 1999-05-14
PCT/EP2000/004261 WO2000071571A2 (fr) 1999-05-14 2000-05-11 Composes anti-tumoraux actives par la proteine fap

Publications (1)

Publication Number Publication Date
SK16452001A3 true SK16452001A3 (sk) 2002-03-05

Family

ID=22461925

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1645-2001A SK16452001A3 (sk) 1999-05-14 2000-05-11 FAB-aktivované protinádorové zlúčeniny, ich prekurzory, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty

Country Status (28)

Country Link
US (1) US6613879B1 (fr)
EP (1) EP1180116A2 (fr)
JP (1) JP3607201B2 (fr)
KR (1) KR20020030270A (fr)
CN (1) CN1213058C (fr)
AR (1) AR033792A1 (fr)
AU (1) AU777521B2 (fr)
BG (1) BG106096A (fr)
BR (1) BR0010564A (fr)
CA (1) CA2369933A1 (fr)
CO (1) CO5170516A1 (fr)
CZ (1) CZ20014097A3 (fr)
EA (1) EA005204B1 (fr)
EE (1) EE200100600A (fr)
HK (1) HK1048642B (fr)
HU (1) HUP0202367A3 (fr)
IL (1) IL145798A0 (fr)
MX (1) MXPA01011401A (fr)
MY (1) MY125939A (fr)
NO (1) NO20015536L (fr)
NZ (1) NZ516075A (fr)
PL (1) PL351680A1 (fr)
SK (1) SK16452001A3 (fr)
TW (1) TWI248444B (fr)
UA (1) UA73506C2 (fr)
WO (1) WO2000071571A2 (fr)
YU (1) YU80901A (fr)
ZA (1) ZA200109151B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068145A2 (fr) 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Medicaments antineoplastiques cibles pouvant etre clives par la peptidase et utilisation therapeutique de ces medicaments
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
GB0027551D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
WO2002089739A2 (fr) * 2001-05-09 2002-11-14 Newbiotics, Inc. Promedicaments actives par peptide deformylase
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1333033A1 (fr) * 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG Composés anti-cancéreux activables par l'FAP
US20030211979A1 (en) * 2002-01-30 2003-11-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor compounds
EP1499318A4 (fr) * 2002-04-18 2006-07-19 Celmed Oncology Usa Inc Promedicaments actives par peptide deformylase
EP1506221A2 (fr) * 2002-05-10 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co.KG Promedicaments antitumoraux actives par la fap
US20040033957A1 (en) * 2002-05-10 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor prodrugs
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
JP2006514009A (ja) * 2002-11-14 2006-04-27 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド ペプチドデホルミラーゼ活性化プロドラッグ
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
EP1625122A1 (fr) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Inhibiteurs de dipeptidyl peptidase
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
WO2006073167A1 (fr) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. Derives de la pyrrolidine
CA2606785A1 (fr) 2005-05-19 2006-11-23 Genentech, Inc. Composes inhibiteurs de proteines d'activation de fibroblastes et procedes
EP1963537A4 (fr) * 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd Procede permettant de diagnostiquer une arthrite rhumatoide par le dosage des synoviocytes de type fibroblastique pour la proteine d'activation des fibroblastes
WO2007087131A2 (fr) * 2006-01-05 2007-08-02 The Johns Hopkins University Promedicaments peptides
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
WO2008005479A2 (fr) * 2006-07-06 2008-01-10 University Of Wyoming Polymères à charge réversible
WO2008116053A2 (fr) * 2007-03-20 2008-09-25 Trustees Of Tufts College Composés chimiothérapeutiques activés par la protéine fap
JP5781930B2 (ja) * 2008-09-12 2015-09-24 カディラ ファーマシューティカルズ リミテッド 新規なジペプチジルペプチダーゼ（ｄｐ−ｉｖ）化合物
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
AU2013369261B2 (en) 2012-12-28 2018-08-09 Cobiores Nv Minimally toxic prodrugs
WO2014169697A1 (fr) * 2013-04-19 2014-10-23 暨南大学 Dérivés de vinblastine, leur procédé de synthèse et leur application
EP3564234B1 (fr) * 2013-11-05 2021-09-29 AstraZeneca AB Promédicaments d'antagonistes de nmda
US9737556B2 (en) * 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
HUE063194T2 (hu) * 2014-06-13 2024-01-28 Bach Biosciences Llc FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
CN105524141B (zh) * 2015-11-12 2019-11-26 中山大学 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用
EP3222292A1 (fr) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Conjugués d'amanitine
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN110128501A (zh) * 2019-05-21 2019-08-16 北京海美源医药科技有限公司 一种靶向fap酶的喜树碱类化合物及其制备方法和应用
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
WO2025200088A1 (fr) * 2024-03-27 2025-10-02 广州医科大学 Conjugué de polypeptide ciblant kras et de petite molécule et son utilisation pour lutter contre le cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915800A (en) * 1972-03-30 1975-10-28 Kelco Co Polysaccharide and bacterial fermentation process for its preparation
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5047401A (en) * 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
ES2053547T3 (es) 1986-07-29 1994-08-01 Sunstar Kk Reactivo para someter a ensayo enfermedades periodontales.
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
EP0855910A4 (fr) 1995-10-18 2000-07-05 Merck & Co Inc Conjugues utiles pour traiter l'adenome prostatique benin
CA2256669A1 (fr) 1996-05-29 1997-12-04 Prototek, Inc. Prodrogues du thalidomide et procedes d'utilisation desdites prodrogues comme modificateurs de cellule t
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
DE69942128D1 (de) 1998-12-11 2010-04-22 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
EP1176985A2 (fr) 1999-04-28 2002-02-06 Vectramed, Inc. Conjugues de medicaments polymeres actives par voie enzymatique

Also Published As

Publication number Publication date
AR033792A1 (es) 2004-01-07
CO5170516A1 (es) 2002-06-27
EP1180116A2 (fr) 2002-02-20
IL145798A0 (en) 2002-07-25
UA73506C2 (en) 2005-08-15
TWI248444B (en) 2006-02-01
JP3607201B2 (ja) 2005-01-05
NO20015536D0 (no) 2001-11-13
AU6559100A (en) 2000-12-12
CA2369933A1 (fr) 2000-11-30
CN1374969A (zh) 2002-10-16
ZA200109151B (en) 2002-12-17
NZ516075A (en) 2004-03-26
EA200101155A1 (ru) 2002-10-31
EE200100600A (et) 2003-02-17
AU777521B2 (en) 2004-10-21
WO2000071571A3 (fr) 2001-09-07
EA005204B1 (ru) 2004-12-30
KR20020030270A (ko) 2002-04-24
HK1048642A1 (en) 2003-04-11
HUP0202367A2 (hu) 2002-11-28
US6613879B1 (en) 2003-09-02
MY125939A (en) 2006-09-29
CN1213058C (zh) 2005-08-03
HK1048642B (zh) 2005-10-28
JP2003500417A (ja) 2003-01-07
MXPA01011401A (es) 2002-06-04
NO20015536L (no) 2002-01-10
WO2000071571A8 (fr) 2002-03-07
HUP0202367A3 (en) 2003-10-28
WO2000071571A2 (fr) 2000-11-30
YU80901A (sh) 2005-07-19
BG106096A (bg) 2002-05-31
PL351680A1 (en) 2003-06-02
CZ20014097A3 (cs) 2002-02-13
BR0010564A (pt) 2002-02-19

Similar Documents

Publication Publication Date Title
US6613879B1 (en) FAP-activated anti-tumour compounds
US20030055052A1 (en) FAP-activated anti-tumor compounds
US20020155565A1 (en) FAP-activated anti-tumor compounds
AU2001266853B2 (en) Prodrug compounds with an oligopeptide having an isoleucine residue
JP2005523264A (ja) Ｆａｐ活性化抗腫瘍化合物
CA2354766A1 (fr) Composes de promedicaments et procede de preparation
JP2004501875A (ja) トリペプチドプロドラッグ化合物
AU2001266853A1 (en) Prodrug compounds with an oligopeptide having an isoleucine residue
KR20030009388A (ko) 펩티다제-절단성인 표적화 항종양 약물 및 그의 치료상 용도
WO2002038590A1 (fr) Composes antitumoraux actives par la proteine fap-alpha
US20030232742A1 (en) FAP-activated anti-tumor compounds
EP1506221A2 (fr) Promedicaments antitumoraux actives par la fap
US20040033957A1 (en) FAP-activated anti-tumor prodrugs
US20030211979A1 (en) FAP-activated anti-tumor compounds
WO2002038591A1 (fr) Composes anticancereux actives par la fap
WO2002038187A1 (fr) Composants iv anti-tumeur fap-actives